Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.
JAMA Neurol. 2014-07-01; 71(7): 884
DOI: 10.1001/jamaneurol.2014.753
Lire sur PubMed
1. JAMA Neurol. 2014 Jul 1;71(7):884-90. doi: 10.1001/jamaneurol.2014.753.
Prevalence, determinants, and effect on quality of life of freezing of gait in
Parkinson disease.
Perez-Lloret S(1), Negre-Pages L(2), Damier P(3), Delval A(4), Derkinderen P(3),
Destée A(5), Meissner WG(6), Schelosky L(7), Tison F(8), Rascol O(1).
Author information:
(1)Department of Clinical Pharmacology, Faculty of Medicine, University Hospital,
University of Toulouse, Toulouse, France2Department of Neurosciences, University
Hospital, University of Toulouse, Toulouse, France3Clinical Investigation Center
1436, Universi.
(2)LN Pharma, Toulouse, France.
(3)Department of Neurology, Hôpital Laënnec, Centre Hospitalier Universitaire
(CHU) Nantes, Nantes, France6NS-Park Network, INSERM, Toulouse, France.
(4)Department of Neurology, CHU Lille, Lille, France.
(5)NS-Park Network, INSERM, Toulouse, France7Department of Neurology, CHU Lille,
Lille, France8INSERM U 837 Eq6, Lille, France.
(6)Institut des Maladies Neurodégénératives, Université de Bordeaux, Bordeaux,
France10Centre National de la Recherche Scientifique, Institut des Maladies
Neurodégénératives, Bordeaux, France11Service de Neurologie, CHU de Bordeaux,
Bordeaux, France.
(7)Neurology Department, Kantonsspital Münsterlingen, Münsterlingen, Switzerland.
(8)NS-Park Network, INSERM, Toulouse, France9Institut des Maladies
Neurodégénératives, Université de Bordeaux, Bordeaux, France10Centre National de
la Recherche Scientifique, Institut des Maladies Neurodégénératives, Bordeaux,
France11Service de Neurologie.
IMPORTANCE: Freezing of gait (FOG) is a common axial symptom of Parkinson disease
(PD).
OBJECTIVE: To determine the prevalence of FOG in a large group of PD patients,
assess its relationship with quality of life and clinical and pharmacological
factors, and explore its changes from the off to on conditions in patients with
motor fluctuations.
DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional survey of 683 patients with
idiopathic PD. Scores for FOG were missing in 11 patients who were not included
in the analysis. Patients were recruited from referral centers and general
neurology clinics in public or private institutions in France.
EXPOSURE: Patients with FOG were identified as those with a score of 1 or greater
on item 14 of the Unified Parkinson’s Disease Rating Scale (UPDRS) in the on
condition. Item 14 scores for FOG in the off condition were also collected in
patients with fluctuating motor symptoms.
MAIN OUTCOMES AND MEASURES: Quality of life (measured by the 39-item Parkinson’s
Disease Questionnaire and 36-Item Short Form Health Survey), anxiety and
depression (Hospital Anxiety and Depression Scale), clinical features (UPDRS),
and drug consumption.
RESULTS: Of 672 PD patients, 257 reported FOG during the onstate (38.2%), which
was significantly related to lower quality of life scores (P